Comparative Pharmacology
Head-to-head clinical analysis: SAXENDA versus TANZEUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAXENDA versus TANZEUM.
SAXENDA vs TANZEUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety via central GLP-1 receptor activation.
Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection once daily, starting at 0.6 mg and titrating weekly by 0.6 mg increments to a maintenance dose of 3.0 mg.
Subcutaneous injection: 300 mg every 4 weeks. Administer as 3 consecutive injections of 100 mg each in the same body region (abdomen, thigh, or upper arm).
None Documented
None Documented
11–13 hours (subcutaneous). Steady-state is reached after 3–5 once-daily doses.
Terminal elimination half-life approximately 5 days (range 4-6 days), supporting weekly subcutaneous dosing
Renal excretion of intact liraglutide is minimal; approximately 6% is excreted as intact liraglutide in urine. The remainder is metabolized and eliminated via the kidneys and feces, with no single metabolite accounting for >10% of the dose.
Renal (79% as unchanged drug), biliary/fecal (minor, ~1%)
Category C
Category C
GLP-1 Receptor Agonist, Anti-obesity
GLP-1 Receptor Agonist